LATEST UPDATES » Vol 23, No 05, May 2019 – What's Cracking Antibodies in ostrich eggs       » China to amend healthcare laws       » First "one-minute clinic" in China university       » Australian gene-editing rules adopt 'middle ground'       » Brexit leads to 25 per cent decline in UK clinical trials       » Wheat that fights celiac disease      
Singapore researchers use AI to successfully treat metastatic cancer
Groundbreaking CURATE.AI platform halts progression of advanced cancer in clinical study by continuously optimising novel drug combination

A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to successfully treat a patient with advanced cancer, completely halting disease progression. This new development represents a big step forward in personalised medicine.

In this clinical study conducted at the UCLA Institute of Urologic Oncology, USA, a patient with metastatic castration-resistant prostate cancer (MCRPC) was given a novel drug combination consisting of investigational drug ZEN-3694 and enzalutamide, an approved prostate cancer drug.

Combination therapy represents a cornerstone in modern cancer treatment. Using this approach, multiple drugs are used to attack the processes that support cancer growth, aiming to achieve drug synergy, where the drugs work together to substantially improve efficacy. It is predominantly given at both fixed as well as high doses and patients are often switched to other drugs when they no longer respond to treatment.

To overcome the challenges of conventional combination therapy, the research team developed the CURATE.AI platform, which uses the patient’s own clinical data – such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood - to calibrate his or her unique response to treatment. This calibration is then used to create an individualised CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time. It can continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.

As a patient’s body and the cancer itself evolve during treatment, the CURATE.AI profile evolves as well. CURATE.AI is applicable to all diseases and all patients.

The research was conducted in collaboration with the University of California, Los Angeles, and Zenith Epigenetics. The findings were published in Advanced Therapeutics on 29 August 2018. In addition, patient recruitment for additional oncology trials in Singapore has been approved.

Click here for the complete issue.

news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Marijuana as medicine — Legal marijuana will open up scientific research
Driven by curiosity
Career developments for researchers
What's cracking — Antibodies in ostrich eggs
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy